PRA Health Sciences, Inc. (NASDAQ:PRAH) – Equities researchers at First Analysis issued their Q3 2018 earnings per share (EPS) estimates for PRA Health Sciences in a note issued to investors on Wednesday. First Analysis analyst S. Schwartz anticipates that the medical research company will earn $1.05 per share for the quarter.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, October 25th. The medical research company reported $0.88 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The firm had revenue of $494.55 million during the quarter, compared to analyst estimates of $477.89 million. During the same quarter in the prior year, the firm posted $0.64 EPS. PRA Health Sciences’s revenue was up 23.7% compared to the same quarter last year. COPYRIGHT VIOLATION WARNING: “PRA Health Sciences, Inc. to Post Q3 2018 Earnings of $1.05 Per Share, First Analysis Forecasts (PRAH)” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.watchlistnews.com/pra-health-sciences-inc-to-post-q3-2018-earnings-of-1-05-per-share-first-analysis-forecasts-prah/1673897.html.

Other analysts have also issued reports about the company. Jefferies Group LLC reiterated a “buy” rating and issued a $92.00 price objective (up from $88.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Citigroup Inc. restated a “buy” rating and set a $93.00 target price (up from $90.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. SunTrust Banks, Inc. reiterated a “buy” rating on shares of PRA Health Sciences in a report on Wednesday, August 9th. Zacks Investment Research upgraded PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 price objective on the stock in a report on Tuesday, August 15th. Finally, BidaskClub cut PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. PRA Health Sciences has a consensus rating of “Buy” and an average price target of $88.09.

In other news, CEO Colin Shannon sold 400,000 shares of the stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $29,940,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $74.85, for a total value of $711,075,000.00. The disclosure for this sale can be found here. Insiders sold 10,000,000 shares of company stock valued at $748,500,000 over the last quarter. Corporate insiders own 2.10% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in PRA Health Sciences by 3.8% during the first quarter. Vanguard Group Inc. now owns 4,659,592 shares of the medical research company’s stock worth $303,946,000 after purchasing an additional 170,812 shares during the period. BlackRock Inc. lifted its holdings in shares of PRA Health Sciences by 28.2% in the second quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock valued at $274,759,000 after purchasing an additional 805,573 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of PRA Health Sciences by 318.3% in the second quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock valued at $163,172,000 after purchasing an additional 1,655,336 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of PRA Health Sciences by 27.5% in the second quarter. Russell Investments Group Ltd. now owns 885,340 shares of the medical research company’s stock valued at $66,409,000 after purchasing an additional 191,109 shares in the last quarter. Finally, Ameriprise Financial Inc. lifted its holdings in shares of PRA Health Sciences by 23.0% in the second quarter. Ameriprise Financial Inc. now owns 788,807 shares of the medical research company’s stock valued at $59,166,000 after purchasing an additional 147,428 shares in the last quarter. 98.48% of the stock is owned by institutional investors.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.